44 results on '"Halley, Frank"'
Search Results
2. Data from Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor
3. Supplementary Data from SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
4. SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
5. The Chemistry of Pentavalent Organobismuth Reagents.: Part 7. The Possible Role of Radical Mechanisms in the Phenylation Process for Bismuth(v), and Related Lead(iv), Iodine(III), and Antimony(v) Reagents
6. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer
7. Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors
8. Abstract 943: SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that demonstrates robust antitumor efficacy and limited cross-resistance in ER+ breast cancer
9. Abstract 5775: Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong anti-tumor activity in wild-type and mutant ER+ breast cancer models
10. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer
11. Preparation and optimization of new 4-(2-(indolin-1-yl)-2-oxoethyl)-2-morpholinothiazole-5-carboxylic acid and amide derivatives as potent and selective PI3Kβ inhibitors
12. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor
13. Differential Water Thermodynamics Determine PI3K-Beta/Delta Selectivity for Solvent-Exposed Ligand Modifications
14. Preparation and optimization of pyrazolo[1,5- a ]pyrimidines as new potent PDE4 inhibitors
15. Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors
16. Selective Oxidation of Saturated Hydrocarbons by the Gif and Gif-Orsay Systems
17. Design of potent and selective GSK3β inhibitors with acceptable safety profile and pharmacokinetics
18. Rational design of potent GSK3β inhibitors with selectivity for Cdk1 and Cdk2
19. Discovery and Optimization of Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatment of Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers
20. Discovery and Optimization of New Benzimidazole- and Benzoxazole-Pyrimidone Selective PI3Kβ Inhibitors for the Treatment of Phosphatase and TENsin homologue (PTEN)-Deficient Cancers
21. ChemInform Abstract: Fe(III)/Cu(II) Mediated 5- and 6-exo Oxidative Ring Expansion/Cyclization of Cyclopropyl Ethers: Studies Towards Dictyol C and α-Eudesmol.
22. ChemInform Abstract: RPR203494 a Pyrimidine Analogue of the p38 Inhibitor RPR200765A with an Improved in vitro Potency.
23. An Algorithm-Directed Two-Component Library Synthesized Via Solid-Phase Methodology Yielding Potent and Orally Bioavailable p38 MAP Kinase Inhibitors
24. RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency
25. The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy
26. Fe(III)/Cu(II) mediated 5- and 6-exo oxidative ring expansion/cyclisation of cyclopropyl ethers: studies towards dictyol C and α-eudesmol
27. Selective ETAAntagonists. 5. Discovery and Structure−Activity Relationships of Phenoxyphenylacetic Acid Derivatives
28. Discovery and Optimizationof Pyrimidone Indoline Amide PI3Kβ Inhibitors for the Treatmentof Phosphatase and Tensin Homologue (PTEN)-Deficient Cancers.
29. Selective Endothelin A Receptor Antagonists. 4. Discovery and Structure−Activity Relationships of Stilbene Acid and Alcohol Derivatives
30. Identification of a non peptidic RANTES antagonist
31. Synthesis of 5-Cyanoindazole and 1-Methyl and 1-Aryl-5-Cyanoindazoles
32. New non peptidic C5a receptor antagonists
33. New Low-Density Lipoprotein Receptor Upregulators Acting via a Novel Mechanism
34. Synthesis of 1,3-disubstituted-pyrrolo[2,1-a]isoquinoline-2-carboxylic acids, esters and amides
35. Discovery and Optimizationof New Benzimidazole- andBenzoxazole-Pyrimidone Selective PI3Kβ Inhibitors for the Treatmentof Phosphatase and TENsin homologue (PTEN)-Deficient Cancers.
36. The chemistry of pentavalent organobismuth reagents. Part 7. The possible role of radical mechanisms in the phenylation process for bismuth(V), and related lead(IV), lodine(III), and antimony(V) reagents.
37. AMINOINDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE OF INTERMEDIATES OF SAID METHOD AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
38. Benzylic oxidation by the gifIV system
39. Functionalization of saturated hydrocarbons. 14. Further studies on the mechanism of Gif-type systems
40. The chemistry of pentavalent organobismuth reagents
41. ChemInform Abstract: RPR203494 a Pyrimidine Analogue of the p38 Inhibitor RPR200765A with an Improved in vitro Potency.
42. ChemInform Abstract: Fe(III)/Cu(II) Mediated 5- and 6-exo Oxidative Ring Expansion/Cyclization of Cyclopropyl Ethers: Studies Towards Dictyol C and α-Eudesmol.
43. Benzylic oxidation by the gif IV system
44. Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3 S )-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7 H -benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.